United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Summary

”United Arab Emirates In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the United Arab Emirates In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the United Arab Emirates In Vitro Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Beckman Coulter, Inc., Abbott Laboratories, Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the United Arab Emirates In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 11
2.1 What is This Report About? 11
3 In Vitro Diagnostics In United Arab Emirates 12
3.1 In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017 12
3.2 In Vitro Diagnostics, United Arab Emirates, Company share (2009-2010) 18
4 Clinical Chemistry In United Arab Emirates 20
4.1 Clinical Chemistry Overall Revenue (2003-2017) 20
4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 24
4.1.2 Urine Analysis Revenue (2003-2017) 28
4.2 Clinical Chemistry Distribution Share (2009-2010) 32
4.3 Clinical Chemistry, United Arab Emirates, Company share (2009-2010) 33
5 Genetic Testing In United Arab Emirates 35
5.1 Genetic Testing Overall Revenue (2003-2017) 35
5.2 Genetic Testing Distribution Share (2009-2010) 39
5.3 Genetic Testing, United Arab Emirates, Company share (2009-2010) 40
6 Haematology In United Arab Emirates 42
6.1 Haematology Overall Revenue (2003-2017) 42
6.1.1 Haematology Reagents Revenue (2003-2017) 46
6.1.2 Immunohaematology Revenue (2003-2017) 50
6.1.3 Haemostasis Revenue (2003-2017) 54
6.1.4 Haematology Rapid Tests Revenue (2003-2017) 58
6.1.5 Haematology Cell Counters Revenue (2003-2017) 62
6.2 Haematology Distribution Share (2009-2010) 66
6.3 Haematology, United Arab Emirates, Company share (2009-2010) 67
7 Histology And Cytology In United Arab Emirates 69
7.1 Histology And Cytology Overall Revenue (2003-2017) 69
7.2 Histology And Cytology Distribution Share (2009-2010) 73
7.3 Histology And Cytology, United Arab Emirates, Company share (2009-2010) 74
8 Immuno Chemistry In United Arab Emirates 76
8.1 Immuno Chemistry Overall Revenue (2003-2017) 76
8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 80
8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 84
8.1.3 Endocrinology Tests Revenue (2003-2017) 88
8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 92
8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 96
8.2 Immuno Chemistry Distribution Share (2009-2010) 100
8.3 Immuno Chemistry, United Arab Emirates, Company share (2009-2010) 101
9 Infectious Immunology In United Arab Emirates 103
9.1 Infectious Immunology Overall Revenue (2003-2017) 103
9.2 Infectious Immunology Distribution Share (2009-2010) 107
9.3 Infectious Immunology, United Arab Emirates, Company share (2009-2010) 108
10 Microbiology Culture In United Arab Emirates 110
10.1 Microbiology Culture Overall Revenue (2003-2017) 110
10.1.1 Microbiology Analyzers Revenue (2003-2017) 114
10.2 Microbiology Culture Distribution Share (2009-2010) 118
10.3 Microbiology Culture, United Arab Emirates, Company share (2009-2010) 119
11 Overview of Key Companies in United Arab Emirates In Vitro Diagnostics Market 121
11.1 F. Hoffmann-La Roche Ltd. 121
11.1.1 Company Overview 121
11.2 Siemens Healthcare 121
11.2.1 Company Overview 121
11.3 Beckman Coulter, Inc. 121
11.3.1 Company Overview 121
11.4 Abbott Laboratories 122
11.4.1 Company Overview 122
11.5 Ortho-Clinical Diagnostics Inc. 122
11.5.1 Company Overview 122
11.6 bioMerieux S.A. 122
11.6.1 Company Overview 122
11.7 The Elitech Group 123
11.7.1 Company Overview 123
11.8 Alere Inc. 123
11.8.1 Company Overview 123
11.9 Becton, Dickinson and Company 123
11.9.1 Company Overview 123
11.10 DiaSorin S.p.A 124
11.10.1 Company Overview 124
11.11 Bio-Rad Laboratories, Inc. 124
11.11.1 Company Overview 124
11.12 Mindray Medical International Limited 124
11.12.1 Company Overview 124
11.13 Phadia AB 125
11.13.1 Company Overview 125
11.14 Thermo Fisher Scientific Inc. 125
11.14.1 Company Overview 125
11.15 HORIBA, Ltd. 125
11.15.1 Company Overview 125
11.16 Sysmex Corporation 126
11.16.1 Company Overview 126
11.17 Grifols, S.A. 126
11.17.1 Company Overview 126
11.18 Qiagen N.V. 126
11.18.1 Company Overview 126
11.19 Gen-Probe Incorporated 127
11.19.1 Company Overview 127
11.20 DIAGNOSTICA STAGO, Inc. 127
11.20.1 Company Overview 127
11.21 Immucor, Inc. 127
11.21.1 Company Overview 127
11.22 PerkinElmer, Inc. 128
11.22.1 Company Overview 128
11.23 Life Technologies Corporation 128
11.23.1 Company Overview 128
11.24 Hologic, Inc. 129
11.24.1 Company Overview 129
11.25 Chembio Diagnostic, Inc. 129
11.25.1 Company Overview 129
12 APPENDIX 130
12.1 Global Markets Direct Research Methodology 130
12.2 Definitions of Markets Covered in the Report 131
12.2.1 In Vitro Diagnostics 131
12.3 Secondary Research 142
12.4 Primary Research 142
12.5 Models 143
12.6 Forecasts 143
12.7 Expert Panel Validation 143
12.8 Currency Conversion 144
12.9 Contact Us 144
12.10 Disclaimer 144

1.1 List of Tables

Table 1: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017 13
Table 2: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Historic, 2003-2010 15
Table 3: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 17
Table 4: In Vitro Diagnostics, United Arab Emirates, Company share by Revenue ($m), USD Actual, 2009-2010 19
Table 5: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 21
Table 6: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 23
Table 7: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 25
Table 8: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 27
Table 9: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 29
Table 10: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 31
Table 11: Clinical Chemistry, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 32
Table 12: Clinical Chemistry, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 34
Table 13: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 36
Table 14: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 38
Table 15: Genetic Testing, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 39
Table 16: Genetic Testing, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 41
Table 17: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 43
Table 18: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 45
Table 19: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 47
Table 20: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 49
Table 21: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 51
Table 22: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 53
Table 23: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 55
Table 24: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 57
Table 25: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 59
Table 26: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 61
Table 27: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 63
Table 28: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 65
Table 29: Haematology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 66
Table 30: Haematology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 68
Table 31: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 70
Table 32: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 72
Table 33: Histology And Cytology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 73
Table 34: Histology And Cytology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 35: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 77
Table 36: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 79
Table 37: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81
Table 38: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83
Table 39: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 85
Table 40: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 87
Table 41: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 89
Table 42: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 91
Table 43: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 93
Table 44: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 95
Table 45: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 97
Table 46: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 99
Table 47: Immuno Chemistry, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 100
Table 48: Immuno Chemistry, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 102
Table 49: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 104
Table 50: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 106
Table 51: Infectious Immunology, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 107
Table 52: Infectious Immunology, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 109
Table 53: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 111
Table 54: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 113
Table 55: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115
Table 56: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117
Table 57: Microbiology Culture, United Arab Emirates, Distribution Share by Revenue ($m), USD Actual, 2009-2010 118
Table 58: Microbiology Culture, United Arab Emirates, Company share by Revenue ($m), USD Actual 2009-2010 120
Table 59: USD to Local Currency, United Arab Emirates, Average Actual Rate 2003-2010 144

1.2 List of Figures

Figure 1: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, 2003-2017 12
Figure 2: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Historic, 2003-2010 14
Figure 3: In Vitro Diagnostics, United Arab Emirates, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 16
Figure 4: In Vitro Diagnostics, United Arab Emirates, Company share (%), 2010 18
Figure 5: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 20
Figure 6: Clinical Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 22
Figure 7: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 24
Figure 8: Clinical Chemisty Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 26
Figure 9: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 28
Figure 10: Urine Analysis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 30
Figure 11: Clinical Chemistry, United Arab Emirates, Company share (%), 2010 33
Figure 12: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 35
Figure 13: Genetic Testing, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 37
Figure 14: Genetic Testing, United Arab Emirates, Company share (%), 2010 40
Figure 15: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 42
Figure 16: Haematology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 44
Figure 17: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 46
Figure 18: Haematology Reagents, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 48
Figure 19: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 50
Figure 20: Immunohaematology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 52
Figure 21: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 54
Figure 22: Haemostasis, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 56
Figure 23: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 58
Figure 24: Haematology Rapid Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 60
Figure 25: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 62
Figure 26: Haematology Cell Counters, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 64
Figure 27: Haematology, United Arab Emirates, Company share (%), 2010 67
Figure 28: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 69
Figure 29: Histology And Cytology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 71
Figure 30: Histology And Cytology, United Arab Emirates, Company share (%), 2010 74
Figure 31: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 76
Figure 32: Immuno Chemistry, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 78
Figure 33: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Figure 34: Disease Specific Immunochemistry, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Figure 35: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 84
Figure 36: Drugs of Abuse / Toxicology, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86
Figure 37: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 88
Figure 38: Endocrinology Tests, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 90
Figure 39: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 92
Figure 40: Therapeutic Drug Monitoring, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 94
Figure 41: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 96
Figure 42: Immunochemistry Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 98
Figure 43: Immuno Chemistry, United Arab Emirates, Company share (%), 2010 101
Figure 44: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 103
Figure 45: Infectious Immunology, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 105
Figure 46: Infectious Immunology, United Arab Emirates, Company share (%), 2010 108
Figure 47: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 110
Figure 48: Microbiology Culture, United Arab Emirates, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 112
Figure 49: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
Figure 50: Microbiology Analyzers, United Arab Emirates, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
Figure 51: Microbiology Culture, United Arab Emirates, Company share (%), 2010 119
Figure 52: Global Markets Direct Methodology 130

Companies Menstion

F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Beckman Coulter, Inc.
Abbott Laboratories
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
The Elitech Group
Alere Inc.
Becton, Dickinson and Company
DiaSorin S.p.A
Bio-Rad Laboratories, Inc.
Mindray Medical International Limited
Phadia AB
Thermo Fisher Scientific Inc.
HORIBA, Ltd.
Sysmex Corporation
Grifols, S.A.
Qiagen N.V.
Gen-Probe Incorporated
DIAGNOSTICA STAGO, Inc.
Immucor, Inc.
PerkinElmer, Inc.
Life Technologies Corporation
Hologic, Inc.
Chembio Diagnostic, Inc.